<DOC>
	<DOCNO>NCT00004689</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine bacteriological activity amithiozone Mycobacterium avium complex ( MAC ) pulmonary disease . II . Define ability amithiozone improve clinical outcome patient MAC infection . III . Determine safety tolerance amithiozone chronic dosing patient . IV . Assess contribution clarithromycin , streptomycin , rifampin , ethambutol , kanamycin , amithiozone treatment pulmonary MAC infection .</brief_summary>
	<brief_title>Phase II Study Amithiozone ( Thiacetazone ) Patients With Mycobacterium Avium Complex Pulmonary Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : The randomized , open label study . All patient receive core regimen clarithromycin streptomycin . Patients randomize two treatment arm . Arm I patient receive rifampin ethambutol . Arm II patient receive amithiozone . Patients follow one year detect relapse complication . Patients eligible randomize study may enter short open label study amithiozone . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Thioacetazone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Progressive pulmonary disease due Mycobacterium avium complex ( MAC ) define : Three sputum culture ( ) positive MAC Change serial chest roentgenogram consistent active mycobacterial disease 12 week period No obvious cause pulmonary disease Patients must organisms : Susceptible amithiozone AND Susceptible moderately susceptible combination rifampin ethambutol , clarithromycin streptomycin Prior/Concurrent Therapy No likelihood resectional thoracic surgery within 24 week evaluation Patient Characteristics Age : 18 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 time normal SGOT/SGPT le 3 time normal Alkaline phosphatase less 3 time normal Renal : Creatinine clearance least 30 mL/min Cardiovascular : No New York Heart Association class III IV heart failure Other : No optic disease precludes use ethambutol No hypersensitivity rifampin , ethambutol , clarithromycin , streptomycin , amithiozone HIV negative Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1999</verification_date>
	<keyword>bacterial infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>mycobacterium avium infection</keyword>
	<keyword>mycobacterium infection</keyword>
	<keyword>rare disease</keyword>
</DOC>